Insights › Medicine & pharma › November 17, 2026
Medicine & pharma · Pipeline & development

Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026

PR Newswire (Health) Published: Trial

Extended Phase 3 INDIGO follow-up results, including data from patients who crossed over to VORANIGO® (vorasidenib) from placebo, were presented as an oral presentation on November 14 Exploratory INDIGO analysis providing insight into VORANIGO's impact on seizure control and quality of...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Medicine & pharma

See everything in Medicine & pharma →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.